Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
about
Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma.Leveraging Genomics for Head and Neck Cancer Treatment.Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
P2860
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Biomarkers predict enhanced cl ...... tastatic head and neck cancer.
@en
Biomarkers predict enhanced cl ...... tastatic head and neck cancer.
@nl
type
label
Biomarkers predict enhanced cl ...... tastatic head and neck cancer.
@en
Biomarkers predict enhanced cl ...... tastatic head and neck cancer.
@nl
prefLabel
Biomarkers predict enhanced cl ...... tastatic head and neck cancer.
@en
Biomarkers predict enhanced cl ...... tastatic head and neck cancer.
@nl
P2093
P2860
P356
P1433
P1476
Biomarkers predict enhanced cl ...... tastatic head and neck cancer.
@en
P2093
A Mailliez
B Burtness
E E W Cohen
E Ehrnrooth
J B Vermorken
J M Del Campo
P2860
P304
P356
10.1093/ANNONC/MDX344
P577
2017-10-01T00:00:00Z